Centerpoint Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.44M | Hold |
1,567
| – | – | 0.47% | 23 |
|
|
2025
Q4 | $1.68M | Sell |
1,567
-12
| -0.8% | -$11.5K | 0.52% | 24 |
|
|
2025
Q3 | $1.21M | Buy |
1,579
+74
| +5% | +$55.1K | 0.37% | 33 |
|
|
2025
Q2 | $1.17M | Hold |
1,505
| – | – | 0.4% | 31 |
|
|
2025
Q1 | $1.24M | Sell |
1,505
-203
| -12% | -$169K | 0.46% | 27 |
|
|
2024
Q4 | $1.32M | Sell |
1,708
-500
| -23% | -$414K | 0.46% | 27 |
|
|
2024
Q3 | $1.96M | Sell |
2,208
-1,236
| -36% | -$1.11M | 0.68% | 20 |
|
|
2024
Q2 | $3.12M | Buy |
3,444
+16
| +0.5% | +$12.8K | 1.12% | 18 |
|
|
2024
Q1 | $2.67M | Sell |
3,428
-5
| -0.1% | -$3.56K | 1% | 17 |
|
|
2023
Q4 | $2M | Sell |
3,433
-335
| -9% | -$196K | 0.79% | 21 |
|
|
2023
Q3 | $2.02M | Sell |
3,768
-453
| -11% | -$233K | 0.86% | 21 |
|
|
2023
Q2 | $1.98M | Sell |
4,221
-192
| -4% | -$80.5K | 0.8% | 23 |
|
|
2023
Q1 | $1.52M | Buy |
4,413
+318
| +8% | +$107K | 0.66% | 25 |
|
|
2022
Q4 | $1.5M | Buy |
4,095
+160
| +4% | +$56.7K | 0.7% | 26 |
|
|
2022
Q3 | $1.27M | Buy |
3,935
+3,175
| +418% | +$1.01M | 0.68% | 23 |
|
|
2022
Q2 | $246K | Hold |
760
| – | – | 0.13% | 73 |
|
|
2022
Q1 | $218K | Hold |
760
| – | – | 0.1% | 78 |
|
|
2021
Q4 | $210K | Sell |
760
-107
| -12% | -$27.1K | 0.09% | 90 |
|
|
2021
Q3 | $200K | Hold |
867
| – | – | 0.1% | 86 |
|
|
2021
Q2 | $199K | Hold |
867
| – | – | 0.09% | 87 |
|
|
2021
Q1 | $162K | Hold |
867
| – | – | 0.1% | 65 |
|
|
2020
Q4 | $146K | Hold |
867
| – | – | 0.09% | 64 |
|
|
2020
Q3 | $128K | Hold |
867
| – | – | 0.1% | 61 |
|
|
2020
Q2 | $142K | Sell |
867
-65
| -7% | -$9.98K | 0.11% | 50 |
|
|
2020
Q1 | $129K | Hold |
932
| – | – | 0.13% | 47 |
|
|
2019
Q4 | $122K | Hold |
932
| – | – | 0.09% | 61 |
|
|
2019
Q3 | $104K | Hold |
932
| – | – | 0.08% | 64 |
|
|
2019
Q2 | $103K | Hold |
932
| – | – | 0.08% | 64 |
|
|
2019
Q1 | $121K | Hold |
932
| – | – | 0.1% | 61 |
|
|
2018
Q4 | $108K | Hold |
932
| – | – | 0.1% | 62 |
|
|
2018
Q3 | $100K | Hold |
932
| – | – | 0.08% | 70 |
|
|
2018
Q2 | $80K | Sell |
932
-408
| -30% | -$33.5K | 0.07% | 75 |
|
|
2018
Q1 | $104K | Buy |
1,340
+26
| +2% | +$2.09K | 0.09% | 63 |
|
|
2017
Q4 | $111K | Buy |
+1,314
| New | +$112K | 0.1% | 48 |
|
Other funds holding LLY
VCM
VPM
Centerpoint Advisors's LLY Position: Q1 2026 in Review
Centerpoint Advisors held its Eli Lilly (LLY) position steady in Q1 2026 at 1,567 shares worth $1.44M. The position accounts for 0.47% of the portfolio, ranked #23.
Centerpoint Advisors first reported a position in LLY in Q4 2017 and has held it in 34 quarters since. The position peaked at $3.12M in Q2 2024. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Centerpoint Advisors held 1,567 shares of Eli Lilly worth $1.44M as of Q1 2026.
- Centerpoint Advisors left its Eli Lilly share count unchanged in Q1 2026.
- Eli Lilly made up 0.47% of Centerpoint Advisors's portfolio in Q1 2026, its #23 holding.
- Centerpoint Advisors first reported a position in Eli Lilly in Q4 2017 and has held it in 34 quarters since.
- Centerpoint Advisors's Eli Lilly position peaked at $3.12M in Q2 2024.
- 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Centerpoint Advisors's 13F filing for Q1 2026, filed 7 May 2026.